Markets:

Overview

News

Currencies

International

Treasuries

Coherus Oncology, Inc. - Common Stock (NQ:CHRS)

1.590 +1.590 (+1589900.00%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Coherus Oncology, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Coherus' Toripalimab/Chemo Combo Cuts Death Risk By 37% In Nasopharyngeal Cancer Patients ↗

June 06, 2023

Via Benzinga

Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma

June 05, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Biotech Alert: Searches Spiking For These Stocks Today - Friday, June 2 ↗

June 02, 2023

Various names in the biotech sector are seeing a substantial increase in search activity today. Such names include the likes of Akebia Therapeautics, Corvus Pharmaceuticals, and Mirati Therapeutics.

Via Talk Markets

Mark Cuban Helping Lower Cost Of Bestselling Humira With Cost Plus Drug Company: 'The Game Just Changed' ↗

June 01, 2023

One of the bestselling medical drugs of all time has come off patent. The result could mean lower costs for those who need the drug as a treatment option. Enter Mark Cuban and his Cost Plus Drug...

Via Benzinga

Why Is AbbVie Stock Trading Down Today? ↗

June 01, 2023

AbbVie Inc. (NYSE: ABBV) shares are trading lower Thursday after Coherus BioSciences Inc.

Via Benzinga

Looking Into Coherus BioSciences's Return On Capital Employed ↗

May 23, 2023

Via Benzinga

6 Analysts Have This to Say About Coherus BioSciences ↗

May 23, 2023

Via Benzinga

Coherus BioSciences Earnings Preview ↗

May 05, 2023

Via Benzinga

Coherus BioSciences's Return On Capital Employed Overview ↗

March 09, 2023

Via Benzinga

Mark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY™, a HUMIRA® biosimilar, available to patients

June 01, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Coherus Announces Industry-Wide Lowest List Price for Adalimumab Biosimilar YUSIMRY™ (adalimumab-aqvh) Launching in July 2023

June 01, 2023

List price of $995 per carton for two 40 mg/0.8 mL autoinjectors

From Coherus BioSciences, Inc.

Via GlobeNewswire

Top 5 Health Care Stocks That Could Blast Off In May ↗

May 26, 2023

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Via Benzinga

Coherus Announces U.S. Launch of UDENYCA® Autoinjector

May 22, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Stocks That Hit 52-Week Lows On Friday ↗

May 19, 2023

On Friday, 63 companies hit new 52-week lows.

Via Benzinga

Coherus Prices Public Offering of Common Stock

May 16, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Vodafone, Calliditas Therapeutics, Rumble And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

May 16, 2023

U.S. stock futures traded mixed this morning. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Coherus Announces Proposed Public Offering of Common Stock

May 15, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Gold Edges Higher; PayPal Shares Tumble Despite Upbeat Earnings ↗

May 09, 2023

U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite dropping around 50 points on Tuesday. The Dow traded down 0.01% to 33,616.00 while the NASDAQ fell 0.43% to...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

May 09, 2023

Via Benzinga

Why PRA Group Shares Are Trading Lower By 44%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

May 09, 2023

Gainers TScan Therapeutics, Inc. (NASDAQ: TCRX) shares gained 118% to $4.68 after the company and Amgen announced collaboration to identify novel targets in Crohn's disease.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

May 09, 2023

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

May 09, 2023

We're starting off the day with the biggest pre-market stock movers traders will want to keep in mind while trading on Tuesday!

Via InvestorPlace

Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights

May 08, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Coherus BioSciences to Present at Upcoming Investor Conferences in May

May 04, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Coherus BioSciences to Report First Quarter 2023 Financial Results on May 8, 2023

May 01, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Analyst Sees A Multibagger, Initiates Coverage On This 'Top Notch Biosimilar Business' ↗

May 01, 2023

Truist initiated coverage on Coherus BioSciences Inc (NASDAQ: CHRS) with a Buy rating and a

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 1, 2023 ↗

May 01, 2023

Via Benzinga

Coherus and Junshi Biosciences Announce Toripalimab Studies to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

April 27, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For March 28, 2023 ↗

March 28, 2023

Via Benzinga

PVH, First Republic Bank And Other Big Stocks Moving Higher In Tuesday's Pre-Market Session ↗

March 28, 2023

U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session.

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.